The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration and Astellas.

Nonadherence to cancer screening varies by screening type and sex, according to a study published online Jan. 3 in JAMA Network Open. Ami E. Sedani, Ph.D., M.P.H., from the University of Texas Health ...